Lunit to Present AI Medical Imaging Analysis Solution Research Abstracts at RSNA 2025

Accelerating Expansion in the US Market

Medical artificial intelligence (AI) company Lunit announced on the 24th that it will present 14 research abstracts related to AI medical imaging analysis solutions at the 2025 Radiological Society of North America (RSNA 2025), which will be held in Chicago, USA, from November 30 to December 4.

Lunit

Notably, out of the 14 research abstracts Lunit will present at this year’s conference, 8 have been selected for oral presentation, which is recognized as a major research achievement at the event. The studies chosen for oral presentation include: ▲ A comparison of DBT interpretation and breast cancer detection performance among four commercial AI algorithms using Dutch breast cancer screening data ▲ A comparison of screening performance based on mammography among seven commercial AI algorithms ▲ The impact of AI on the decision-making and gaze behavior of radiologists ▲ A paradigm shift in breast cancer screening from traditional double reading to AI-integrated double reading and further to AI-integrated single reading ▲ A comparison of AI software accuracy for pneumothorax detection in chest X-rays. Research related to breast density and breast cancer risk analysis will also be presented, including: ▲ A comparison between high-risk estimates using breast density and existing risk prediction models ▲ The effect of changes in breast density on the calibration and accuracy of risk prediction models ▲ A study comparing the correlation between breast density and pathological prognostic stages in the UK breast cancer screening program, all of which will be presented orally.

Poster presentations will include: ▲ Optimization of AI-positive findings for early detection of contralateral breast cancer after breast cancer surgery ▲ Analysis of breast cancer subtypes that are easily missed by AI in DBT ▲ Comparison and synergy analysis of breast cancer prediction performance between biophysical models and commercial breast density assessment-based models ▲ Risk score prediction in estrogen receptor-positive breast cancer ▲ Prediction of axillary lymph node metastasis after neoadjuvant chemotherapy ▲ Prediction of pathological complete response to neoadjuvant chemotherapy.

Seo Bumseok, CEO of Lunit, stated, "At this year’s RSNA 2025, we will showcase research achievements spanning various areas where Lunit’s AI technology is applied, from breast cancer screening and risk prediction to lung disease diagnosis." He added, "As many of the studies demonstrate the real-world impact of AI in clinical settings, we expect significant interest from both academia and industry."

Meanwhile, at RSNA 2025, Lunit will operate a joint booth with Lunit International (formerly Volpara). This will be the first Lunit booth since the brand integration, where visitors can experience end-to-end AI solutions covering everything from cancer diagnosis to risk prediction. The company also plans to accelerate its expansion in the US market through networking and partnership discussions with global partners.

This content was produced with the assistance of AI translation services.